Although last month's 10th International Conference on AIDS in Yokohama, Japan, yielded little in the way of good news concerning progress to date in efforts to combat the pandemic, some researchers were able to leave the meeting with the hope that future gatherings will be less gloomy. William E. Paul, head of the National Institutes of Health's Office of AIDS Research, announced a measure to encourage innovative approaches to basic AIDS research with federal funds gained by cutting current financial support of unpromising clinical trials of AIDS-related vaccines and drugs. The move was welcomed by, among others, Bernard N. Fields, chairman of the department of microbiology and molecular genetics at Harvard Medical School in Boston, who recently called for just such a realignment of funding priorities (Nature, 369:95-6, May...
Interested in reading more?
Become a Member of
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member?